{
  "ticker": "LLY",
  "target_date": "2025-01-21",
  "actual_date": "2025-01-21",
  "collected_at": "2025-12-08T11:18:10.059229",
  "price": {
    "open": 725.86,
    "high": 737.78,
    "low": 721.15,
    "close": 736.8538208007812,
    "volume": 5122800,
    "change_1d_pct": 2.29,
    "change_7d_pct": -5.7,
    "change_30d_pct": -10.54
  },
  "technicals": {
    "rsi_14": 39.2,
    "sma_20": 766.32,
    "sma_50": 775.35,
    "macd": -12.13,
    "macd_signal": -8.271,
    "macd_histogram": -3.859,
    "bb_upper": 808.16,
    "bb_lower": 724.48,
    "price_vs_sma20_pct": -3.85,
    "price_vs_sma50_pct": -4.97,
    "volume_ratio": 1.31
  },
  "fundamentals": {
    "market_cap": 888998264832,
    "pe_ratio": 48.587948,
    "forward_pe": 43.76346,
    "price_to_book": 37.33735,
    "price_to_sales": 14.961314,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.82,
    "pct_from_52w_low": 58.98
  },
  "macro": {
    "spy": {
      "price": 597.81,
      "change_1d_pct": 0.92,
      "change_7d_pct": 3.89
    },
    "vix": {
      "level": 15.06,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.57
    },
    "dollar_index": {
      "level": 108.06
    },
    "gold": {
      "price": 2755.0
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer\u2019s, Study Shows. What It Means for the Stocks.",
      "source": "MarketWatch",
      "datetime": 1737459540,
      "summary": "Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer\u2019s, Study Shows. What It Means for the Stocks.",
      "url": "https://finnhub.io/api/news?id=5d34a1e430ec5cf462b5066b308b6b07863b41a2039e90394ab8ad224cf9d0c4"
    },
    {
      "headline": "Overvaluation And Record Highs: Why The Bull Market Might Still Have Room To Run",
      "source": "SeekingAlpha",
      "datetime": 1737442800,
      "summary": "The stock market\u00e2\u0080\u0099s brief downturn appears to be ending. Learn more about many high-quality blue-chip bargains that remain available.",
      "url": "https://finnhub.io/api/news?id=e77e88b101eb5e67d7421f9d90a4827f92457674eb4c75ea97abed6d231b8421"
    },
    {
      "headline": "Eli Lilly: Market Overreacted",
      "source": "SeekingAlpha",
      "datetime": 1737437923,
      "summary": "Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas. See why LLY stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=f7cdd8e327108d81abd628c532e2840f2ab5c21a7d8cd9ab4282b61b3eec1ee7"
    },
    {
      "headline": "Viking Therapeutics: The Turning Point Is Not Here Yet",
      "source": "SeekingAlpha",
      "datetime": 1737383698,
      "summary": "Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma remains risky.",
      "url": "https://finnhub.io/api/news?id=13352d11da720b6f820b3d891efe5ba459d5c223aa5daaf2ec4bd3b9bb12ead0"
    },
    {
      "headline": "Carillon ClariVest Capital Appreciation Fund Q4 2024 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1737373020,
      "summary": "At the start of the quarter, Carillon ClariVest Capital Appreciation Fund vs. Russell 1000 Growth Index, was most overweight the healthcare and financials sectors.",
      "url": "https://finnhub.io/api/news?id=54cf828d9caeaafcb426d9422ac96510c78190fca07684df97dbf1bdbb80c73c"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "8-K",
      "date": "2025-01-14",
      "description": "lly-20250114.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000005/lly-20250114.htm"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470584.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000291/xslF345X05/wk-form4_1734470584.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470498.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000289/xslF345X05/wk-form4_1734470498.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470366.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000287/xslF345X05/wk-form4_1734470366.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470270.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000285/xslF345X05/wk-form4_1734470270.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}